## Recursion Pharmaceuticals (RXRX) Sees Bullish Analyst Reassessment – What's Behind the Rally?

Recursion Pharmaceuticals just got a shot in the arm from Wall Street. Analysts collectively lifted their one-year price target to **$7.14 per share**, up 10.53% from the previous $6.46 consensus. That might not sound dramatic, but here's the kicker: compared to RXRX's current market price of $4.26, the upside potential sits at a hefty **67.61%**. The range of individual analyst estimates spans from $3.03 on the bearish end to $11.55 on the optimistic side – showing divided opinion, though the consensus tilts decidedly bullish.

## Institutional Heavy-Hitters Are Actively Repositioning

The institutional playbook for Recursion tells an interesting story of selective repositioning. Currently, **505 funds and institutions** maintain positions in the biotech firm, though this represents a slight pullback of 22 holders from the prior quarter. Here's what stands out:

**ARK Investment Management** remains the largest institutional backer, controlling **33,545K shares** (6.52% ownership). The firm bumped up its holding by 1.66% sequentially but paradoxically trimmed its portfolio weight by 20.38% – suggesting selective profit-taking despite maintaining conviction.

**Baillie Gifford**, the second major player, holds **23,979K shares** (4.66% stake) but has been quietly trimming exposure. The fund decreased both its absolute position by 0.81% and portfolio allocation by 5.12%.

Meanwhile, the **ARK Innovation ETF** expanded its RXRX position by 6.50% to **19,950K shares**, even as it rebalanced overall allocation downward by 27.92% – a classic sign of tactical adjustments rather than fundamental doubt.

Other notable holders include **Softbank Group** with 14,667K shares (2.85%) and **Kinnevik AB** with 13,434K shares (2.61%), both maintaining steady stakes.

## Market Sentiment Increasingly Positive

The put/call ratio of **0.24** signals predominantly bullish positioning among options traders. Total institutional ownership expanded by 4.20% over the past three months to **378,294K shares**, despite the modest decline in the number of fund holders. Average fund portfolio allocation to RXRX sits at 0.18%, up 0.59% – incremental but meaningful given the competitive biotech landscape.

The divergence between rising analyst targets, stable-to-growing institutional ownership, and growing derivatives bullishness suggests the market is pricing in positive developments ahead for Recursion's pipeline or operational momentum.